INMB — Inmune Bio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1711754 ·
Last close
$2.36
Market Cap
$65.50M
52W High
$2.48
52W Low
$1.20
ADV30
423,924
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -1,476,000 | -1,273,000 | 26,845,000 | 18,411,000 | 6,483,000 |
| Mar 2026 | 0 | — | -5,812,000 | -5,407,000 | 25,818,000 | 21,358,000 | 6,194,000 |
| Dec 2025 | 0 | — | -5,474,000 | -5,264,000 | 32,351,000 | 24,751,000 | 8,827,000 |
| Sep 2025 | 0 | — | -7,433,000 | -6,472,000 | 33,358,000 | 27,734,000 | 7,980,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,961,000
Investing CF
$-336,000
Financing CF
$816,000
CapEx
$-336,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.54
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-215,717,000
Inventory
—
Receivables
$4,767,000
ST Investments
—
EBIT TTM
$-20,195,000
Pretax Income TTM
$-18,416,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
—
Free Cash Flow
$-10,046,875
Enterprise Value
$48,492,944
Total Cash
$18,411,000
Total Debt
$1,405,000
Shares Out
27,753,789
Trailing EPS
$-0.64
Book Value
$0.74
ROE
-74.8%
ROA
-39.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 50,000 | -30,869,000 | -45,933,000 | 32,351,000 | 8,827,000 | — | -22,582,000 |
| Dec 2024 | 14,000 | -42,635,000 | -42,082,000 | 39,562,000 | 7,465,000 | — | -33,361,000 |
| Dec 2023 | 155,000 | -29,741,000 | -30,008,000 | 57,001,000 | 18,862,000 | — | -11,980,000 |
| Dec 2022 | 374,000 | -25,951,000 | -27,299,000 | 81,795,000 | 21,691,000 | — | -22,686,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.49
Max Pain — expiry 2026-09-18
max pain strike: $2.00 · spot: $2.37 · call oi: 2,032 · put oi: 192
Expected Move to 2026-09-18:
±$0.65
(27.22%) —
implied range
$1.72 –
$3.01
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EXOZ | EXOZYMES INC. | $64.51M | $6.95 | — |
| IMA | ImageneBio, Inc. | $63.80M | $5.62 | — |
| ENZN | Viskase Holdings, Inc. | $67.50M | $4.71 | — |
| ELOX | Eloxx Pharmaceuticals, Inc. | $68.69M | $19.99 | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $69.05M | $4.97 | — |
News headlines (Yahoo Finance, 1h cache)
INmune Bio (INMB) Q2 2026 Earnings Call Transcript
2026-08-07 06:11 · Yahoo
INmune Bio Inc (INMB) (Q2 2026) Earnings Call Highlights: Regulatory Wins and Strategic Focus ...
2026-08-07 05:08 · Yahoo
INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress
2026-08-06 20:00 · Yahoo
INmune Bio Receives R&D Rebates of Approximately $4.6 Million
2026-07-31 11:00 · Yahoo
INmune Bio Establishes Scientific Advisory Board to Support Late-Stage Development and Expansion of CORDStrom™ Platform
2026-07-30 11:00 · Yahoo
INmune Bio’s XPro1595 Prevents Brain-Injury-Induced Alzheimer's Pathology, Memory Loss, and Pain in New Peer-Reviewed Preclinical Study
2026-07-15 11:00 · Yahoo
INmune Bio to Present Positive Phase 2 Imaging Data for XPro in Early Alzheimer’s Disease at AAIC
2026-07-09 11:00 · Yahoo
INmune Bio Inc. Achieves MHRA Approval of PIP for CORDStrom™
2026-06-25 11:00 · Yahoo
INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB
2026-06-23 12:00 · Yahoo
INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial
2026-06-02 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.